Allergen-specific Immunotherapy (AIT) is currently the only allopathic treatment capable of modifying the natural course of immunoglobulin E (IgE)-mediated allergic diseases. Currently, there is a lack of recognized clinical markers for evaluating and predicting the efficacy of AIT, and some biological markers may have some potential for application. This article will summarize the currently known indicators for evaluating and predicting the therapeutic effects of AIT, with the aim of providing assistance in evaluating and monitoring the efficacy of AIT.

The prevalence of allergic diseases is on the rise,posing a significant global health challenge.Allergen specific immunotherapy(AIT)is the only treatment capable of altering the natural course of allergic diseases,offering long-term efficacy and the potential to prevent disease progression.However,its widespread application is hindered by factors such as lengthy treatment duration,adverse reactions,and patient compliance issues.In recent years,biologics targeting type 2 inflammatory pathways have played a crucial role at various stages of different allergic diseases.Research indicates that for patients with moderate to severe allergic diseases,using biologics during or prior to AIT can significantly enhance the safety of AIT,reduce the time required to reach maintenance doses,and markedly improve symptom scores.This article elucidates the synergistic mechanisms and recent advancements in the combined application of biologics and AIT in the treatment of allergic diseases.The aim is to provide a reference for the standardized treatment of allergic diseases.

Allergen-specific Immunotherapy (AIT) is currently the only allopathic treatment capable of modifying the natural course of immunoglobulin E (IgE)-mediated allergic diseases. Currently, there is a lack of recognized clinical markers for evaluating and predicting the efficacy of AIT, and some biological markers may have some potential for application. This article will summarize the currently known indicators for evaluating and predicting the therapeutic effects of AIT, with the aim of providing assistance in evaluating and monitoring the efficacy of AIT.

The prevalence of allergic diseases is on the rise,posing a significant global health challenge.Allergen specific immunotherapy(AIT)is the only treatment capable of altering the natural course of allergic diseases,offering long-term efficacy and the potential to prevent disease progression.However,its widespread application is hindered by factors such as lengthy treatment duration,adverse reactions,and patient compliance issues.In recent years,biologics targeting type 2 inflammatory pathways have played a crucial role at various stages of different allergic diseases.Research indicates that for patients with moderate to severe allergic diseases,using biologics during or prior to AIT can significantly enhance the safety of AIT,reduce the time required to reach maintenance doses,and markedly improve symptom scores.This article elucidates the synergistic mechanisms and recent advancements in the combined application of biologics and AIT in the treatment of allergic diseases.The aim is to provide a reference for the standardized treatment of allergic diseases.

Objective To analyze the predictive value of cyclin-dependent activator 3(CDKN3)in the prog-nosis of oral squamous cell carcinoma(OSCC)and its relationship with immune cell infiltration,and to ex-plore the biological function of CDKN3 in the occurrence and development of OSCC.Methods RNAseq data related to OSCC were obtained from the Cancer Genome Atlas and Gene Expression Omnibus database.The expression level of CDKN3,prognostic value,clinicopathological features and immune cell infiltration were an-alyzed by R language and statistical methods.Gene enrichment analysis was used to analyze the biological role of CDKN3 in OSCC.Results Compared with normal tissues,CDKN3 was highly expressed in OSCC tumor tissues(P＜0.01),and the area under curve for the receiver operating characteristic curve was 0.955.The pa-tients with high expression of CDKN3 had a poor prognosis(P=0.024).The expression of CDKN3 was cor-related with pathological stage(P＜0.05)and histological grade(P＜0.001).There was a significant differ-ence in the level of immune cell infiltration between the CDKN3 high and low expression groups(P＜0.05).Functional enrichment analysis showed that CDKN3 was closely related to cell cycle.Conclusion CDKN3 may be a potential carcinogenic risk factor of OSCC,which is related to the clinicopathological characteristics,prog-nosis and immune cell infiltration of patients.CDKN3 may be a diagnostic biomarker and a potential therapeu-tic target for OSCC.

Objective:To compare the epidemiological and clinical characteristics of influenza A (IVA) and influenza B (IVB) in children of different ages, genders and seasons from 2016 to 2019.Methods:Retrospective analysis was performed on the children who were diagnosed as infected with influenza A and B virus in the outpatient and emergency department of Shanghai Eighth People′s Hospital from 2016 to 2019, including 2388 cases of influenza A virus infection and 1 575 cases of influenza B virus infection. The age, gender, time, characteristics of onset, and common indicators of blood routine tests were compared.Results:influenza virus infection is mostly prevalent from December to March of the next year, mainly influenza A virus, with minor epidemics from August to October of the next year, and influenza B virus from April to June of the next year. Compared with influenza B virus, children with respiratory tract infection caused by influenza A virus had higher WBC count, neutrophil, lymphocyte and monocyte abnormal proportions. The incidence rate of respiratory tract infection in the group infected with IVA was significantly higher ( P<0.05), and the incidence of infection in children among different age groups was significantly different ( P<0.05). Conclusions:The proportion of leukocyte and neutrophil increased, the lymphocyte was normal or decreased, and monocyte percentage increased in influenza A patients, which are more common than in influenza B patients, but the rate of abnormal increase of WBC was more common in influenza B cases. Children infected with influenza A are more likely to have anemia and platelet abnormality, and children with respiratory tract infection caused by the two viruses have different age groups. However, there was no significant difference between male and female.

OBJECTIVETo investigate the clinicopathologic features, immunohistochemic phenotypes and genetic alterations of extrapulmonary inflammatory myofibroblastic tumor (IMT) and the correlation with prognosis.

METHODSThirty cases of IMT with follow-up were analyzed morphologically and immunohistochemically. ALK FISH was also performed to determine the ALK gene status.

RESULTSPatients ranged in age from 12 to 73 years (mean 43.4 years). The male-to-female ratio was 1.0: 1.1. The tumors were located in various anatomical sites including gastrointestinal tract, liver, spleen, kidney, pelvic, retroperitoneum, mediastinum etc. Histologically, the majority of cases were composed of spindled fibroblastic and myofibroblastic cells accompanied by an inflammatory infiltrate of plasma cells, lymphocytes, and eosinophils. Most cases with aggressive behavior had features including prominent nucleoli and edematous myxoid background. Lymphohistiocytic reactions were usually absent. Some cases showed multinucleation, nuclear pleomorphism and mitoses. One case demonstrated epithelioid morphology with round-to-epithelioid cells. The immunohistochemical study showed vimentin, SMA, CK, desmin, and ALK were expressed in 100% (30/30), 70% (21/30), 13% (4/30), 27% (8/30), and 27% (8/30) of IMT, respectively. Diffuse cytoplasmic ALK staining was detected in seven cases. One case (containing round-to-epithelioid cells) demonstrated ALK nuclear membrane staining, coupled with positive reaction for CD30 and negative reaction for LCA. EMA, CD34, CD117 and S-100 protein, and MyoD1 were negative for all cases. Six ALK protein positive cases harbored ALK gene rearrangement, but not the remaining 22 cases. Follow-up data were available in 21 patients. After initial resection, 14 patients were alive with no evidence of disease, while 4 patients were alive with tumor recurrence and 3 patients died of the disease.

CONCLUSIONSMost IMT with aggressive behavior have features including prominent nucleoli, edematous myxoid background, and positive expression of ALK. Lymphohistiocytic reaction is usually absent. ALK may be a potential novel therapeutic target for IMT.

Adolescent ; Adult ; Aged ; Child ; Female ; Fibroblasts ; pathology ; Granuloma, Plasma Cell ; genetics ; pathology ; Humans ; Inflammation ; pathology ; Male ; Middle Aged ; Myofibroblasts ; pathology ; Prognosis ; Receptor Protein-Tyrosine Kinases ; genetics ; Young Adult